Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
2022 · PLoS ONE · 22 citations
https://doi.org/10.1371/journal.pone.0267027